NCT02487550尚未招募2 期
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 1,200
- 主要终点
- Overall-survival time
研究概览
简要总结
The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.
详细描述
The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regime.
Primary
- Determine the clinical responses(objective response, progression-free survival, and overall survival) in patients with renal cell carcinoma treated with autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) in combination with Cytokine-Induced Killer Cell (CIK).
Secondary
- Determine cellular immune response response in terms of immuknow assay, and correlate immune response with objective clinical response in patients treated with this regimen.
- Determine safety of multiple administrations of this regimens in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven renal cell carcinoma
- •Age: > 18
- •WHO- ECOG Performance Status 0-1
- •At least one measurable tumor lesions according to the RECIST criteria.
- •Life expectancy more than 3 months
- •Written informed consent
排除标准
- •Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin).
- •Patients with metastatic disease in the central nervous system (CNS).
- •Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.
- •Patients with acute or chronic infection including HIV.
- •Patients who are pregnant or nursing.
- •Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial.
- •Patients who receive corticosteroids or other immunosuppressive agents.
- •Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.
结局指标
主要结局
Overall-survival time
时间窗: 3 months
Progression-free time
时间窗: 3 months
次要结局
- Objective tumor response(3 months)
研究者
xiaodong li
Principal Investigator
The First People's Hospital of Changzhou
相似试验
Unknown
1 期
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell CarcinomaRenal Cell CarcinomaNCT00862303Fuzhou General Hospital100
终止
1 期
Dendritic Cell Based Therapy of Metastatic Breast CancerMetastatic Breast CancerNCT00197925Herlev Hospital40
Unknown
2 期
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of TreatmentGastric CancerNCT02504229Beijing Biohealthcare Biotechnology Co.,Ltd80
已完成
1 期
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)GlioblastomaNCT02709616Guangdong 999 Brain Hospital10
已完成
1 期
Dendritic Cell Based Therapy of Renal Cell CarcinomaAdvanced Renal Cell CarcinomaNCT00197860Inge Marie Svane40